Destruxin B

Destruxin B, isolated from entomopathogenic fungus Metarhizium anisopliae , is one of the cyclodepsipeptides with insecticidal and anticancer activities. Destruxin B induces apoptosis via a Bcl-2 Family -dependent mitochondrial pathway in human nonsmall cell lung cancer cells Destruxin B significantly activates caspase-3 and reduces tumor cell proliferation through caspase-mediated apoptosis , not only in vitro but also in vivo . In Vitro Destruxin B (1-30 μM; 48 hours) inhibits cell proliferation of H1299 cells and A549 cells, with IC 50 s of 4.1 μM and 4.9 μM, respectively. Activation of mitochondria-dependent caspase cascade plays an important role in Destruxin B (1-30 μM; 48 hours) induced apoptotic cell death in A549 cells. Destruxin B (1.25-20.00 μM; 72 hours) treatment significantly inhibits HT-29 human colorectal cancer cells viability in time- and dose-dependent manners. Destruxin B (10 or 20 μM; 12 and 24 hours) treatment markedly increases levels of the proapoptotic protein PUMA and reduces levels of antiapoptotic proteins Mcl-1 of A549 cells in a concentration- and time-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: H1299 cells Concentration: 1, 5, 10, 20, 30 μM Incubation Time: 48 hours Result: Inhibited H1299 cells proliferation of H1299 cells with an IC 50 of 4.1 μM. Apoptosis AnalysisCell Line: Lung adenocarcinoma A549 cells Concentration: 1, 5, 10, 20, 30 μM Incubation Time: 48 hours Result: Induces caspase-dependent Lung adenocarcinoma A549 cells death. Cell Viability AssayCell Line: HT-29 human colorectal cancer cells Concentration: 1.25, 2.50, 5.00, 10.00 and 20.00 μM Incubation Time: 72 hours Result: The IC 50 s at 24 h, 48 h and 72h were determined as 14.97, 2.00 and 0.67 μM, respectively. Western Blot AnalysisCell Line: A549 cells Concentration: 10 or 20 μM Incubation Time: 12 and 24 hours Result: Regulates Mcl-1 and PUMA. In Vivo Destruxin B (DB) ( injection; 0.6-15 mg/kg/day for 6 weeks) attenuates the tumor growth in time- and dose-dependent manners. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Athymic female nude mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl), approximately 4-5 weeks old on arrivalDosage: Low dose (0.6 mg/kg), medium dose (3 mg/kg), high dose (15 mg/kg) Administration: Injection; daily; for 6 weeks Result: Low dose, medium dose and high dose indicated a reduction of 23.9%, 33.4% and 55.8% in mean tumor size, respectively. Form:Solid IC50& Target:Bcl-2 Caspase-3

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet